Antibiotics in childhood pneumonia: how long is long enough?

Keith Grimwood, Siew Moy Fong, Mong How Ooi, Anna Nathan, Anne Chang

    Research output: Contribution to journalArticle

    Abstract

    Improved access to healthcare, vaccines and treatment with antibiotics has reduced global mortality from childhood community-acquired pneumonia. However, as respiratory viruses are responsible for most episodes of pneumonia, important questions remain over who should receive these agents and the length of each treatment course. Worldwide concerns with increasing antibiotic resistance in respiratory pathogens and appeals for more prudent antibiotic prescribing provide further urgency to these clinical questions. Unfortunately, guidelines for treatment duration in particular are based upon limited (and often weak) evidence, resulting in national and international guidelines recommending treatment courses for uncomplicated pneumonia ranging from 3 to 10 days. The advantages of short-course therapy include a lower risk of developing antibiotic resistance, improved adherence, fewer adverse drug effects, and reduced costs. The risks include treatment failure, leading to increased short- or long-term morbidity, or even death. The initial challenge is how to distinguish between bacterial and non-bacterial causes of pneumonia and then to undertake adequately powered randomised-controlled trials of varying antibiotic treatment durations in children who are most likely to have bacterial pneumonia. Meanwhile, healthcare workers should recognise the limitations of current pneumonia treatment guidelines and remember that antibiotic course duration is also determined by the child’s response to therapy. Community-acquired pneumonia is the leading global cause of childhood morbidity and mortality. Annually, there are an estimated 120–160 million clinical pneumonia episodes worldwide, causing 14 million hospitalisations and almost one million deaths in children aged <5 years [1, 2]. Although respiratory viruses are the most common pathogens associated with childhood pneumonia, most deaths are attributed to Streptococcus pneumoniae and Haemophilus influenzae type b [3]. Consequently, antibiotics have reduced pneumonia-related morbidity and mortality. Nevertheless, several knowledge gaps exist with prescribing antibiotics for pneumonia, including the optimal length of treatment required. These limitations are evident in both national and international guidelines, which have had to rely upon expert opinion and weak levels of evidence from a small number of clinical trials with substantial methodological limitations [4–7]. A good example of these difficulties is the range of recommendations provided on treatment duration for uncomplicated childhood pneumonia [5, 6]. This raises several questions for healthcare workers when determining how long they should be giving antibiotics to a child with pneumonia.
    Original languageEnglish
    Pages (from-to)1-3
    Number of pages3
    JournalPneumonia
    Volume8
    DOIs
    Publication statusPublished - 11 May 2016

    Fingerprint Dive into the research topics of 'Antibiotics in childhood pneumonia: how long is long enough?'. Together they form a unique fingerprint.

  • Cite this